BPG is committed to discovery and dissemination of knowledge
Opinion Review
Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Aug 15, 2026; 18(8): 120240
Published online Aug 15, 2026. doi: 10.4251/wjgo.v18.i8.120240
Figure 1
Figure 1 Schematic illustration of the dual role of E74-like E26 transformation-specific transcription factor 3 in gastric cancer progression. A: E74-like E26 transformation-specific transcription factor 3 (ELF3) binds the CDH1 promoter to inhibit E-cadherin expression, inducing epithelial-mesenchymal transition; B: ELF3 binds the CXCL11 promoter to inhibit its expression, impairing CD8+ T cell recruitment. This figure is based on the model proposed by Sun et al[21], which presently has support from binding evidence and correlational data, but functional validation remains to be supplemented. The diagram is drawn by Figdraw (www.figdraw.com). EMT: Epithelial-mesenchymal transition; ELF3: E74-like E26 transformation-specific transcription factor 3; CTL: Cytotoxic T lymphocyte.


Write to the Help Desk